Listed

Celldex Therapeutics, Inc.

CLDXNasdaqCIK 744218HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$22.0k, Q2 FY2026
Operating income−$80.6m, Q2 FY2026
Net income−$73.5m, Q2 FY2026
Celldex Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m1.5Revenue, Q3 FY2023, three months to 2023-09-30$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure4.1Revenue, Q4 FY2023, three months to 2023-12-31$4.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure0.2Revenue, Q1 FY2024, three months to 2024-03-31$156.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure2.5Revenue, Q2 FY2024, three months to 2024-06-30$2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure3.2Revenue, Q3 FY2024, three months to 2024-09-30$3.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure1.2Revenue, Q4 FY2024, three months to 2024-12-31$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure0.7Revenue, Q1 FY2025, three months to 2025-03-31$695.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure0.7Revenue, Q2 FY2025, three months to 2025-06-30$730.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001104659-25-109137. Derived: 9-month figure less the 6-month figure.Report this figure0.1Revenue, Q4 FY2025, three months to 2025-12-31$121.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$15.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$22.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Research and development$m34.5Research and development, Q3 FY2023, three months to 2023-09-30$34.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure30.4Research and development, Q4 FY2023, three months to 2023-12-31$30.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure31.7Research and development, Q1 FY2024, three months to 2024-03-31$31.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure39.7Research and development, Q2 FY2024, three months to 2024-06-30$39.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure45.3Research and development, Q3 FY2024, three months to 2024-09-30$45.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure46.9Research and development, Q4 FY2024, three months to 2024-12-31$46.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure52.6Research and development, Q1 FY2025, three months to 2025-03-31$52.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure54.2Research and development, Q2 FY2025, three months to 2025-06-30$54.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure62.9Research and development, Q3 FY2025, three months to 2025-09-30$62.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure75.3Research and development, Q4 FY2025, three months to 2025-12-31$75.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure73.0Research and development, Q1 FY2026, three months to 2026-03-31$73.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure67.5Research and development, Q2 FY2026, three months to 2026-06-30$67.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Operating income$m(41.2)Operating income, Q3 FY2023, three months to 2023-09-30−$41.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure(47.6)Operating income, Q4 FY2023, three months to 2023-12-31−$47.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(40.6)Operating income, Q1 FY2024, three months to 2024-03-31−$40.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure(46.3)Operating income, Q2 FY2024, three months to 2024-06-30−$46.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure(52.1)Operating income, Q3 FY2024, three months to 2024-09-30−$52.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure(56.0)Operating income, Q4 FY2024, three months to 2024-12-31−$56.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(62.7)Operating income, Q1 FY2025, three months to 2025-03-31−$62.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(63.9)Operating income, Q2 FY2025, three months to 2025-06-30−$63.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure(73.6)Operating income, Q3 FY2025, three months to 2025-09-30−$73.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure(87.2)Operating income, Q4 FY2025, three months to 2025-12-31−$87.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(84.4)Operating income, Q1 FY2026, three months to 2026-03-31−$84.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(80.6)Operating income, Q2 FY2026, three months to 2026-06-30−$80.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(38.3)Net income, Q3 FY2023, three months to 2023-09-30−$38.3m. XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure(43.3)Net income, Q4 FY2023, three months to 2023-12-31−$43.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(32.8)Net income, Q1 FY2024, three months to 2024-03-31−$32.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure(35.8)Net income, Q2 FY2024, three months to 2024-06-30−$35.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure(42.1)Net income, Q3 FY2024, three months to 2024-09-30−$42.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure(47.1)Net income, Q4 FY2024, three months to 2024-12-31−$47.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(53.8)Net income, Q1 FY2025, three months to 2025-03-31−$53.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure(56.6)Net income, Q2 FY2025, three months to 2025-06-30−$56.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure(67.0)Net income, Q3 FY2025, three months to 2025-09-30−$67.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure(81.3)Net income, Q4 FY2025, three months to 2025-12-31−$81.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(78.7)Net income, Q1 FY2026, three months to 2026-03-31−$78.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure(73.5)Net income, Q2 FY2026, three months to 2026-06-30−$73.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Diluted EPS$ per share(0.81)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figurenot reported(0.56)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure(0.54)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure(0.64)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figurenot reported(0.81)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(0.85)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure(1.01)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figurenot reported(1.18)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(0.94)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Basic EPS$ per share(0.81)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figurenot reported(0.56)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure(0.54)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure(0.64)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figurenot reported(0.81)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(0.85)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure(1.01)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figurenot reported(1.18)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(0.94)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.94 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure

Balance sheet

Cash and equivalents$47.5m, Q2 FY2026
Shareholders' equity$714.6m, Q2 FY2026
Celldex Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m21.1Cash and equivalents, Q3 FY2023, at 2023-09-30$21.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-02, accession 0001410578-23-002169.Report this figure34.8Cash and equivalents, FY2023, at 2023-12-31$34.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0001410578-25-000216.Report this figure115Cash and equivalents, Q1 FY2024, at 2024-03-31$115.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-06, accession 0001410578-24-000593.Report this figure42.7Cash and equivalents, Q2 FY2024, at 2024-06-30$42.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001410578-24-001219.Report this figure36.4Cash and equivalents, Q3 FY2024, at 2024-09-30$36.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure28.4Cash and equivalents, FY2024, at 2024-12-31$28.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-25, accession 0001104659-26-019652.Report this figure17.1Cash and equivalents, Q1 FY2025, at 2025-03-31$17.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure23.0Cash and equivalents, Q2 FY2025, at 2025-06-30$23.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure36.0Cash and equivalents, Q3 FY2025, at 2025-09-30$36.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure28.9Cash and equivalents, FY2025, at 2025-12-31$28.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure35.7Cash and equivalents, Q1 FY2026, at 2026-03-31$35.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure47.5Cash and equivalents, Q2 FY2026, at 2026-06-30$47.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Current assets$m246Current assets, Q3 FY2023, at 2023-09-30$245.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0001410578-23-002169.Report this figure432Current assets, FY2023, at 2023-12-31$431.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0001410578-25-000216.Report this figure835Current assets, Q1 FY2024, at 2024-03-31$835.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-06, accession 0001410578-24-000593.Report this figure812Current assets, Q2 FY2024, at 2024-06-30$812.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001410578-24-001219.Report this figure779Current assets, Q3 FY2024, at 2024-09-30$778.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure747Current assets, FY2024, at 2024-12-31$747.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-25, accession 0001104659-26-019652.Report this figure694Current assets, Q1 FY2025, at 2025-03-31$693.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure648Current assets, Q2 FY2025, at 2025-06-30$648.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure604Current assets, Q3 FY2025, at 2025-09-30$604.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure535Current assets, FY2025, at 2025-12-31$534.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure459Current assets, Q1 FY2026, at 2026-03-31$459.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure725Current assets, Q2 FY2026, at 2026-06-30$724.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Total assets$m280Total assets, Q3 FY2023, at 2023-09-30$280.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0001410578-23-002169.Report this figure466Total assets, FY2023, at 2023-12-31$465.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0001410578-25-000216.Report this figure869Total assets, Q1 FY2024, at 2024-03-31$868.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-06, accession 0001410578-24-000593.Report this figure846Total assets, Q2 FY2024, at 2024-06-30$845.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001410578-24-001219.Report this figure823Total assets, Q3 FY2024, at 2024-09-30$823.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure792Total assets, FY2024, at 2024-12-31$792.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-25, accession 0001104659-26-019652.Report this figure739Total assets, Q1 FY2025, at 2025-03-31$739.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure692Total assets, Q2 FY2025, at 2025-06-30$692.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure648Total assets, Q3 FY2025, at 2025-09-30$648.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure583Total assets, FY2025, at 2025-12-31$583.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure511Total assets, Q1 FY2026, at 2026-03-31$511.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure782Total assets, Q2 FY2026, at 2026-06-30$782.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Current liabilities$m27.8Current liabilities, Q3 FY2023, at 2023-09-30$27.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0001410578-23-002169.Report this figure31.1Current liabilities, FY2023, at 2023-12-31$31.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0001410578-25-000216.Report this figure26.3Current liabilities, Q1 FY2024, at 2024-03-31$26.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-06, accession 0001410578-24-000593.Report this figure27.7Current liabilities, Q2 FY2024, at 2024-06-30$27.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001410578-24-001219.Report this figure32.1Current liabilities, Q3 FY2024, at 2024-09-30$32.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure39.5Current liabilities, FY2024, at 2024-12-31$39.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-25, accession 0001104659-26-019652.Report this figure32.0Current liabilities, Q1 FY2025, at 2025-03-31$32.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure33.0Current liabilities, Q2 FY2025, at 2025-06-30$33.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure46.5Current liabilities, Q3 FY2025, at 2025-09-30$46.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure51.0Current liabilities, FY2025, at 2025-12-31$51.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure51.5Current liabilities, Q1 FY2026, at 2026-03-31$51.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure61.3Current liabilities, Q2 FY2026, at 2026-06-30$61.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Total liabilities$m33.5Total liabilities, Q3 FY2023, at 2023-09-30$33.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0001410578-23-002169.Report this figure36.5Total liabilities, FY2023, at 2023-12-31$36.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0001410578-25-000216.Report this figure30.2Total liabilities, Q1 FY2024, at 2024-03-31$30.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-06, accession 0001410578-24-000593.Report this figure31.9Total liabilities, Q2 FY2024, at 2024-06-30$31.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001410578-24-001219.Report this figure37.3Total liabilities, Q3 FY2024, at 2024-09-30$37.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure45.3Total liabilities, FY2024, at 2024-12-31$45.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-25, accession 0001104659-26-019652.Report this figure36.5Total liabilities, Q1 FY2025, at 2025-03-31$36.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure37.0Total liabilities, Q2 FY2025, at 2025-06-30$37.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure50.1Total liabilities, Q3 FY2025, at 2025-09-30$50.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure55.8Total liabilities, FY2025, at 2025-12-31$55.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure55.0Total liabilities, Q1 FY2026, at 2026-03-31$55.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure67.8Total liabilities, Q2 FY2026, at 2026-06-30$67.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure
Shareholders' equity$m247Shareholders' equity, Q3 FY2023, at 2023-09-30$246.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure429Shareholders' equity, FY2023, at 2023-12-31$429.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-25, accession 0001104659-26-019652.Report this figure839Shareholders' equity, Q1 FY2024, at 2024-03-31$838.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure814Shareholders' equity, Q2 FY2024, at 2024-06-30$813.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure786Shareholders' equity, Q3 FY2024, at 2024-09-30$785.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure747Shareholders' equity, FY2024, at 2024-12-31$747.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure703Shareholders' equity, Q1 FY2025, at 2025-03-31$703.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure655Shareholders' equity, Q2 FY2025, at 2025-06-30$655.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure598Shareholders' equity, Q3 FY2025, at 2025-09-30$598.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure527Shareholders' equity, FY2025, at 2025-12-31$527.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure456Shareholders' equity, Q1 FY2026, at 2026-03-31$456.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure715Shareholders' equity, Q2 FY2026, at 2026-06-30$714.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure

Cash flow

Operating cash flow−$57.4m, Q2 FY2026
Capital expenditure$3.2m, Q2 FY2026
Celldex Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(19.0)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$19.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0001410578-24-001766. Derived: 9-month figure less the 6-month figure.Report this figure(32.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$32.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(40.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$40.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure(29.3)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$29.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001410578-25-001610. Derived: 6-month figure less the 3-month figure.Report this figure(55.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$55.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001104659-25-109137. Derived: 9-month figure less the 6-month figure.Report this figure(32.5)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$32.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(54.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$54.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(44.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$44.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091984. Derived: 6-month figure less the 3-month figure.Report this figure(48.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$48.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001104659-25-109137. Derived: 9-month figure less the 6-month figure.Report this figure(63.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$63.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure(65.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$65.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure(57.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$57.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091984. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.2Capital expenditure, Q3 FY2023, three months to 2023-09-30$157.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0001410578-24-001766. Derived: 9-month figure less the 6-month figure.Report this figure0.7Capital expenditure, Q4 FY2023, three months to 2023-12-31$666.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2024, three months to 2024-03-31$344.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure0.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$274.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001410578-25-001610. Derived: 6-month figure less the 3-month figure.Report this figure0.5Capital expenditure, Q3 FY2024, three months to 2024-09-30$545.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001104659-25-109137. Derived: 9-month figure less the 6-month figure.Report this figure0.8Capital expenditure, Q4 FY2024, three months to 2024-12-31$756.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2025, three months to 2025-03-31$265.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure0.7Capital expenditure, Q2 FY2025, three months to 2025-06-30$728.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091984. Derived: 6-month figure less the 3-month figure.Report this figure0.4Capital expenditure, Q3 FY2025, three months to 2025-09-30$440.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001104659-25-109137. Derived: 9-month figure less the 6-month figure.Report this figure1.3Capital expenditure, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001104659-26-019652. Derived: 12-month figure less the 9-month figure.Report this figure1.6Capital expenditure, Q1 FY2026, three months to 2026-03-31$1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure3.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$3.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091984. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)77.84m, Q2 FY2026
Celldex Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3046,916 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001410578-23-002169.Report this figure0.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3147,214 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-06, accession 0001410578-24-000593.Report this figure0.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3047,253 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001410578-24-001219.Report this figure0.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3047,261 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0001410578-24-001766.Report this figure0.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3158,871 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001410578-25-001111.Report this figure0.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3066,019 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001410578-25-001610.Report this figure0.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3066,294 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure66.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3166,383,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure66.4Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3066,392,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure0.1Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3066,420 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001104659-25-109137.Report this figure66.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3166,566,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057113.Report this figure77.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3077,840,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure

Shares outstanding: 78.53mShares outstanding, period not labelled, at 2026-07-2978,529,532 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091984.Report this figure at Jul 29, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. Listed shows no prices and gives no investment advice.